Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus Target Price from Brokerages

Theravance Biopharma, Inc. (NASDAQ:TBPH) has been given a consensus recommendation of “Hold” by the five research firms that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $13.75.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, February 25th.

Theravance Biopharma Trading Down 0.1 %

Shares of NASDAQ TBPH opened at $9.30 on Friday. The company has a market capitalization of $460.08 million, a price-to-earnings ratio of -9.21 and a beta of 0.15. Theravance Biopharma has a twelve month low of $7.44 and a twelve month high of $10.90. The business has a 50 day simple moving average of $9.37 and a 200-day simple moving average of $9.08.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.26). The business had revenue of $18.75 million for the quarter, compared to the consensus estimate of $29.90 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. As a group, equities analysts predict that Theravance Biopharma will post -1.09 earnings per share for the current year.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now owns 309,565 shares in the company, valued at approximately $2,786,085. This trade represents a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Theravance Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Barclays PLC boosted its position in Theravance Biopharma by 279.9% during the 3rd quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock worth $529,000 after acquiring an additional 48,316 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Theravance Biopharma by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 266,879 shares of the biopharmaceutical company’s stock valued at $2,151,000 after purchasing an additional 7,620 shares in the last quarter. Algert Global LLC acquired a new stake in Theravance Biopharma in the third quarter worth about $851,000. Jane Street Group LLC grew its position in Theravance Biopharma by 1.1% in the 3rd quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock valued at $1,165,000 after buying an additional 1,640 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Theravance Biopharma by 88.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock valued at $2,462,000 after buying an additional 143,781 shares during the period. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.